And the winner of Startup Battlefield at Disrupt 2026 is: Intero Biosystems

Biotech startups are now developing more advanced organoid models for drug discovery, potentially reducing the need for animal testing.

Intero Biosystems has won the Startup Battlefield competition at TechCrunch Disrupt 2026, receiving a $100,000 prize. The Denver-based startup, which spun out of the University of Michigan, develops 1mm human intestinal organoids, lab-grown tissue that simulates the gut for drug and compound testing. Their flagship product, GastroScreen, is marketed to pharmaceutical, biotech, food, and chemical companies. The competition featured 20 startups, narrowed down to five finalists. Apate, an Australian startup that uses AI agents to identify and analyze scams, was the runner-up. Intero Biosystems and Apate join a list of notable past Battlefield winners and finalists.

Intero Biosystems' win highlights the growing investment and interest in advanced biological models for pharmaceutical research. The company's intestinal organoids offer a more predictive in-vitro system for drug efficacy and toxicity, potentially accelerating the drug development pipeline and reducing costs for biotech and pharma companies. This technology could significantly alter pre-clinical testing protocols. The recognition at Disrupt signifies a maturing market for these complex biological tools. Competitors like Apate also underscore the increasing sophistication of AI in cybersecurity, particularly in proactive threat intelligence. By deploying AI agents to engage with potential scams, Apate provides a unique data stream for understanding and mitigating fraud. The dual focus on biotech innovation and advanced AI defense at Disrupt suggests a market receptive to deep-tech solutions addressing critical industry challenges.

The success of Intero Biosystems and the strong showing of other deep-tech startups at Disrupt indicates a potential shift in venture capital focus. Investors are increasingly looking beyond software-as-a-service to invest in companies with complex scientific or hardware-based solutions that solve fundamental problems. This trend could empower more research-intensive startups to secure funding and bring groundbreaking technologies to market. As more companies like Intero Biosystems emerge, the pharmaceutical and biotech industries may see a significant acceleration in the pace of innovation. The ability to test drug candidates more effectively and efficiently in these advanced models could lead to faster drug approvals and a wider range of therapeutic options. The broader tech industry will likely see spillover effects as computational biology and AI intersect in novel ways.